BONAZZETTI, CECILIA MARIA
 Distribuzione geografica
Continente #
AS - Asia 2.361
NA - Nord America 1.245
EU - Europa 984
SA - Sud America 131
Continente sconosciuto - Info sul continente non disponibili 109
AF - Africa 75
OC - Oceania 21
Totale 4.926
Nazione #
US - Stati Uniti d'America 1.190
CN - Cina 648
IT - Italia 600
VN - Vietnam 574
SG - Singapore 568
HK - Hong Kong 149
KR - Corea 135
BR - Brasile 91
BD - Bangladesh 85
IN - India 61
DE - Germania 59
NL - Olanda 54
FR - Francia 51
JP - Giappone 47
GB - Regno Unito 42
CI - Costa d'Avorio 41
RU - Federazione Russa 32
CA - Canada 30
FI - Finlandia 30
IE - Irlanda 24
AR - Argentina 23
AT - Austria 20
SE - Svezia 19
AU - Australia 18
ZA - Sudafrica 15
IQ - Iraq 14
TW - Taiwan 13
TH - Thailandia 12
ID - Indonesia 11
PL - Polonia 11
PH - Filippine 10
MX - Messico 9
ES - Italia 8
BG - Bulgaria 7
TR - Turchia 7
JO - Giordania 6
PK - Pakistan 6
SA - Arabia Saudita 6
JM - Giamaica 5
UA - Ucraina 5
CH - Svizzera 4
CO - Colombia 4
EC - Ecuador 4
PY - Paraguay 4
SC - Seychelles 4
BE - Belgio 3
CL - Cile 3
DK - Danimarca 3
LT - Lituania 3
NI - Nicaragua 3
TN - Tunisia 3
AL - Albania 2
CY - Cipro 2
EG - Egitto 2
HN - Honduras 2
MA - Marocco 2
PR - Porto Rico 2
SK - Slovacchia (Repubblica Slovacca) 2
UZ - Uzbekistan 2
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
DZ - Algeria 1
ET - Etiopia 1
FJ - Figi 1
GD - Grenada 1
GH - Ghana 1
GR - Grecia 1
KE - Kenya 1
MK - Macedonia 1
MU - Mauritius 1
NA - Namibia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
OM - Oman 1
PE - Perù 1
PG - Papua Nuova Guinea 1
PS - Palestinian Territory 1
PT - Portogallo 1
RO - Romania 1
SV - El Salvador 1
VE - Venezuela 1
VI - Stati Uniti Isole Vergini 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZM - Zambia 1
Totale 4.818
Città #
Singapore 416
Hefei 313
Ashburn 200
Ho Chi Minh City 170
San Jose 150
Bologna 147
Hong Kong 129
Seoul 128
Hanoi 120
Dallas 91
Santa Clara 72
Milan 68
Council Bluffs 62
New York 57
Boardman 46
Los Angeles 42
Abidjan 41
Beijing 41
Tokyo 40
Bengaluru 34
Rome 30
Da Nang 29
Castel Maggiore 26
Lauterbourg 25
Buffalo 23
Dublin 23
São Paulo 23
Haiphong 16
Vienna 15
Frankfurt am Main 14
Munich 14
Can Tho 13
Boydton 12
Helsinki 12
Modena 12
Adelaide 11
Chicago 11
Johannesburg 11
Lappeenranta 11
Nuremberg 11
Redondo Beach 11
Turin 11
Florence 10
Quận Bình Thạnh 10
Amsterdam 9
London 9
Shanghai 9
Catania 8
Genoa 8
Montreal 8
Rimini 8
Tongling 8
Toronto 8
Warsaw 8
Atlanta 7
Bến Tre 7
Cesena 7
Denver 7
Guangzhou 7
Hải Dương 7
Naples 7
Paris 7
San Lazzaro di Savena 7
Sofia 7
Thái Nguyên 7
Turku 7
Amman 6
Bangkok 6
Chandler 6
Ha Long 6
Jakarta 6
Orem 6
Palermo 6
The Dalles 6
Verona 6
Berlin 5
Buenos Aires 5
Bắc Ninh 5
City of London 5
Falkenstein 5
Hyderabad 5
Miami 5
Padua 5
Pavia 5
Secaucus 5
Baghdad 4
Bari 4
Bhubaneswar 4
Biên Hòa 4
Budrio 4
Cagliari 4
Catanzaro 4
Ferrara 4
Houston 4
Jeddah 4
Lunano 4
Moscow 4
Mumbai 4
Nanjing 4
Ninh Bình 4
Totale 3.082
Nome #
Artificial Intelligence model to predict resistances in Gram-negative bloodstream infections 311
Relationship between immune response to SARS-CoV2 vaccines and development of breakthrough infection in solid organ transplant recipients: the CONTRAST cohort 274
Epidemiological characteristics and management of Gram-negative bacteraemia in different immunocompromised hosts: Observational single-center study 218
Exploring parvovirus B19 pathogenesis and therapy among kidney transplant recipients: case report and review of literature 217
Impact of attaining an aggressive PK/PD target with continuous infusion beta-lactams on the clinical efficacy of targeted therapy of early post-transplant Gram-negative infections in critically ill OLT recipients. An interim analysis of a 3-year prospective, observational, study 213
Tolerability of pulsed high-dose L-AmB as pre-emptive therapy in patients at high risk for intra-abdominal candidiasis: A phase 2 study (LAMBDA study) 199
A pre-post quasi-experimental study of antimicrobial stewardship exploring the impact of a multidisciplinary approach aimed at attaining an aggressive joint pharmacokinetic/pharmacodynamic target with ceftazidime/avibactam on treatment outcome of KPC-producing Klebsiella pneumoniae infections and on ceftazidime/avibactam resistance development 198
Risk factors associated with bacteremia in COVID-19 patients admitted to intensive care unit: a retrospective multicenter cohort study 193
Clinical phenotypes and quality of life to define post-COVID-19 syndrome: a cluster analysis of the multinational, prospective ORCHESTRA cohort 188
Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin–Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing Enterobacterales Secondary Bloodstream Infections: Findings from a Prospective Pilot Study 185
Validation of the INCREMENT-SOT-CPE score in a large cohort of liver transplant recipients with carbapenem-resistant Enterobacterales infection 180
Comparison between available early antiviral treatments in outpatients with SARS-CoV-2 infection: a real-life study 178
Enterococcus faecium bacteraemia: a multicentre observational study focused on risk factors for clinical and microbiological outcomes 172
COVID-19 clinical phenotypes in vaccinated and nonvaccinated solid organ transplant recipients: a multicenter validation study 167
A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: A strategy useful for raising the bar? 161
Using machine learning to predict antibody response to SARS-CoV-2 vaccination in solid organ transplant recipients: the multicentre ORCHESTRA cohort 161
Long-term immune response after SARS-CoV2 vaccination in solid organ transplant recipients 155
Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections? 154
Effect of a Fourth Dose of mRNA Vaccine and of Immunosuppression in Preventing SARS-CoV-2 Breakthrough Infections in Heart Transplant Patients 138
Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis 138
The impact of preservation fluid culture on graft site arteritis: a systematic review and metanalysis 129
Impact on clinical outcome of follow-up blood cultures and risk factors for persistent bacteraemia in patients with gram-negative bloodstream infections: a systematic review with meta-analysis 116
Survey on the approach to antibiotic prophylaxis in liver and kidney transplant recipients colonized with “difficult to treat” Gram‐negative bacteria 105
HHV8-related diseases in solid organ transplantation: a case series and systematic literature review 103
Comparison between available early antiviral treatments in outpatients with SARS-CoV-2 infection: a real-life study 97
ORCHESTRA Delphi consensus: diagnostic and therapeutic management of SARS-CoV-2 infection in haematological patients 97
Association of Patients’ Epidemiological Characteristics and Comorbidities with Severity and Related Mortality Risk of SARS-CoV-2 Infection: Results of an Umbrella Systematic Review and Meta-Analysis 97
Implementation of a Bundle for the Management of Patients With Gram-Negative Bloodstream Infection: A Pre-Post Quasi-experimental Study 66
Pan-European Fragile Populations Cohort for COVID-19: What Worked, What Didn't, and Lessons Learned 65
Aggressive joint pharmacokinetic/pharmacodynamic target attainment of TDM-guided continuous infusion meropenem-vaborbactam monotherapy: a valuable strategy for maximizing the microbiological outcome of documented KPC-producing Enterobacterales infections? 56
The controversial bond between COVID-19 and bacterial superinfections 54
ORCHESTRA Delphi consensus: diagnostic and therapeutic management of SARS-CoV-2 infection in patients with rheumatological diseases 53
From clinical trials to daily practice: How to adequately administer sulbactam-durlobactam? alone or combined with imipenem? 49
Impact of HCV eradication with direct-acting antiviral agents on serum gamma globulin levels in HCV and HCV/HIV coinfected patients 39
Totale 4.926
Categoria #
all - tutte 11.710
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.710


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202221 0 0 0 0 0 0 0 0 4 7 6 4
2022/2023104 3 5 1 3 25 7 1 7 27 5 11 9
2023/2024213 14 11 7 10 12 19 13 23 16 38 22 28
2024/2025864 31 65 52 63 82 31 44 50 27 67 139 213
2025/20263.516 310 493 342 324 216 93 352 123 549 226 233 255
2026/2027208 91 117 0 0 0 0 0 0 0 0 0 0
Totale 4.926